Ababneh Obada, Abushukair Hassan, Qarqash Aref, Syaj Sebawe, Al Hadidi Samer
Faculty of Medicine, Jordan University of Science and Technology, P.O. 22110, Irbid, Jordan.
Myeloma Center, Winthrop P. Rockefeller Cancer Institute, University of Arkansas for Medical Sciences, Little Rock, AR USA.
Clin Hematol Int. 2022 May 23;4(1-2):21-29. doi: 10.1007/s44228-022-00007-5. eCollection 2022 Jun.
The use of Bruton Tyrosine Kinase (BTK) inhibitors in Waldenström's Macroglobulinemia (WM) is evolving. Ibrutinib, a first-generation BTK inhibitor, is currently approved for use in frontline and relapsed/refractory disease. Second-generation BTK inhibitors are being used and studied to improve clinical outcomes and/or safety profile. Zanubrutinib, one such second-generation inhibitor, was recently approved in treatment-naive and refractory/relapsed patients. Here, we review the use of BTK inhibitors in WM in front-line and refractory or relapsed settings. We also highlight common adverse events, the emergence of BTK inhibitors resistance, and future directions of their use.
布鲁顿酪氨酸激酶（BTK）抑制剂在华氏巨球蛋白血症（WM）中的应用正在不断发展。第一代BTK抑制剂伊布替尼目前已获批用于一线治疗以及复发/难治性疾病。第二代BTK抑制剂正在被使用和研究，以改善临床疗效和/或安全性。泽布替尼就是这样一种第二代抑制剂，最近已获批用于初治以及难治性/复发性患者。在此，我们回顾BTK抑制剂在WM一线治疗以及难治性或复发性疾病中的应用。我们还强调了常见的不良事件、BTK抑制剂耐药性的出现以及其未来的应用方向。
